FDA con­cerns at con­trac­tor Catal­ent site spurred on short­ages of No­vo Nordisk's semaglu­tide — re­port

Just be­fore the start of the new year, No­vo Nordisk re­vealed its sup­ply of obe­si­ty med We­govy was low and that it would not be …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA